Study Drug Accountability Sample Clauses

Study Drug Accountability. ‌‌ The investigator, or designee, will maintain a record of all study drug received, dispensed, and returned to the Sponsors’ designee. No study drug shall be destroyed by the clinical site unless directed in writing to do so by the Sponsor’s quality assurance department. Study drug bottles and any unused capsules should be returned to the study staff for eventual disposition by the Sponsor. The number of capsules returned at each visit will be recorded for each bottle in the kit.
Sample 1
AutoNDA by SimpleDocs
Study Drug Accountability. Upon receipt of study drug, the Investigator or designee will inspect the materials and follow the instructions regarding receipt in the Pharmacy Manual. A copy of the shipping documentation will be kept in the study files. The study drug provided is for use only as directed in this protocol. The Investigator or designee must maintain a record of all study drug received, used, and discarded. It must be clear from the records which subject received which kit of active or placebo treatment. If a dose adjustment is deemed necessary by the Investigator at any time during the treatment period (see Section 9.3 for dose adjustment criteria), the subject will be instructed to return to the site to return any remaining current dose and for the adjusted dose to be dispensed. Sage or designee will be permitted access to the study supplies at any time within usual business hours and with appropriate notice during or after completion of the study to perform drug accountability reconciliation.
Sample 1
Study Drug Accountability. ‌ An accurate and current accounting of the dispensing and return of study drug for each subject will be maintained on an ongoing basis by a member of the study site staff. The number of bags dispensed and returned by the subject and the volume remaining will be recorded on the Investigational Drug Accountability Record.
Sample 1
Study Drug Accountability. The study drug will be stored in accordance with Decree No. 4.6 Evidence Hodnoceného přípravku. Hodnocené léčivo bude v souladu s vyhláškou č. 226/2008 Coll., as amended, in the Institution’s Pharmacy, which undertakes to comply with the conditions of the good pharmacy practice and the associated instructions of SÚKL and guarantees handling of the drug by authorized persons only. 226/2008 Sb., v platném znění, uskladněno v Lékárně zdravotnického zařízení, která se zavazuje dodržovat podmínky správné lékárenské praxe, související pokyny SÚKL a zaručuje manipulaci s léčivem pouze oprávněnými osobami. The shipment of the study drug will be delivered to the address: "Lékárna FNO" (Hospital Pharmacy)17. listopadu 000000 000 Xxxxxxx - Xxxxxx Xxxxx Xxxxxxxx and identified with the protocol number„APL2-GA-305“The FNO Pharmacy will be responsible for receiving the shipment of the study drug and for dispensing the study drugto the Investigator or his/her designee. Institution and Investigator or their authorized designee will: (a) verify receipt of the Study Drug by signing the appropriate documentation provided by Sponsor or its designee; (b) store all Study Drug securely as designated in the Protocol; (c) document the administration of the Study Drug to Study Subjects; (d) only dispense the Study Drug to Study Subjects in accordance with the Protocol; and (e) upon completion or early termination of the Study, destroy or return to Sponsor or its designee, at Sponsor’s expense, all unused Study Drug, as well as any containers (whether containing unused Study Drug or not) in accordance with Sponsor’s instructions or as set forth in the Protocol. These arrangements shall also apply to all study drugs provided by the Sponsor under the Study that have passed their expiration date. Zásilka Hodnoceného přípravku bude dodána na adresu:„Lékárna FNO“17. listopadu 179070 852 Ostrava – PorubaČeská republikaoznačena číslem protokolu „APL2-GA-305“ Lékárna Zdravotnického zařízení bude zodpovídat za příjem zásilky Hodnoceného přípravku a výdej Hodnoceného přípravku Zkoušejícímu lékaři nebo xxx xxxxxxxx osobě. Zdravotnické zařízení a Zkoušející lékař nebo xxx xxxxxxxx zástupce: (a) ověří přijetí Hodnoceného přípravku podpisem příslušné dokumentace poskytnuté Zadavatelem nebo jeho zástupcem; (b) bezpečně uloží veškerý Hodnocený přípravek způsobem stanoveným v Protokolu; (c) dokumentuje podávání Hodnoceného přípravku Subjektům hodnocení; d) vydá Hodnocený přípravek pouze Subjektům ho...
Sample 1
Study Drug Accountability. The investigator will maintain accurate records of receipt of all study drug, including dates of receipt. Accurate records will be kept regarding when and how much study drug is dispensed and used by each subject in the study. Reasons for departure from the expected dispensing regimen must also be recorded. Study drug accountability will be recorded in the subject source documentation, entered into the eCRF, and should be reviewed by the monitor during each monitoring visit. On a regular basis and at the completion of the study, to satisfy regulatory requirements regarding drug accountability, all study drug will be reconciled and retained or destroyed according to applicable regulations.
Sample 1
Study Drug Accountability. Each study drug shipment will include a packing slip, explaining the contents of the shipment, and drug return instructions and forms. The investigator is responsible for ensuring that deliveries of study drug and other study materials from the sponsor are correctly received and recorded, handled and stored safely and properly in accordance with the CFR or local regulations, and used in accordance with this protocol. A record of study drug accountability (ie, study drug and other materials received, used, returned, or destroyed) must be prepared and signed by the principal investigator or designee, with an account given for any discrepancies. Empty, partially used, and unused vials of study drug will be destroyed at the study center or returned to ImmuPharma or its designee.
Sample 1
Study Drug Accountability. All used (empty and partially empty) and unused LJPC-501 vials must be saved for reconciliation by the Study Monitor or Clinical Research Associate (CRA). Following final reconciliation, all used and unused vials of LJPC-501 are to be returned to La Jolla or its designee for destruction, or destroyed (if approved by La Jolla) at the site.
Sample 1
AutoNDA by SimpleDocs
Study Drug Accountability. The Principal Investigator is responsible for ensuring that an inventory is conducted upon receipt of the clinical supplies. The temperature recorder from the shipment will be deactivated and authorized study staff will verify that the temperature was maintained at - 20°C during transit. The clinical supplies shipment form should be completed, signed, and returned as directed. A copy must be maintained at the site for the Principal Investigator's records. The Principal Investigator will keep a current record of the inventory, storage conditions and dispensing of all study drugs. This record will be made available to RIBOMIC (or designee) for accounting for all clinical supplies. Any significant discrepancy and/or deficiency must be recorded with an explanation. All supplies sent to the Principal Investigator must be accounted for and in no case will study drugs be used in any unauthorized situation. It is the responsibility of the Principal Investigator to ensure that any used and unused supplies are available to RIBOMIC (or designee) throughout the study.
Sample 1
Study Drug Accountability. ‌ The investigator or designee will maintain an accurate record of the receipt of the study medications as shipped by Aclaris Therapeutics, Inc. (or designee), including the date received and the condition of the study medications. One copy of this receipt will be returned to Aclaris Therapeutics, Inc. (or designee) when the contents of the study medication shipment have been verified and one copy maintained in the study file. In addition, an accurate study medication disposition record will be kept, specifying the amount dispensed for each subject and the date of dispensing. This inventory record will be available for inspection at any time. At the completion of the study, the original inventory record will be available for review by Aclaris Therapeutics, Inc. upon request. Final drug accountability will be completed by the study monitor at the completion of the study and all unused study medication will be returned to Aclaris Therapeutics, Inc. drug depot for disposal per Aclaris Therapeutics, Inc. (or designee’s) written instructions.
Sample 1

Related to Study Drug Accountability

  • Accountability 5.3.1 Actuaries and external auditors will be appointed by the Trust. Audited financial statements, and an actuarial evaluation report will be obtained for the Trust on an annual basis. The actuarial report will include projections regarding the adequacy of contributions to cover projected benefit and related costs for the Trust for a period of not less than 3 years into the future.

  • Fiscal Accountability A. SUBRECIPIENT shall establish and maintain a sound financial management system, based upon generally accepted accounting principles. SUBRECIPIENT’s system shall provide fiscal control and accounting procedures that will include the following:

  • Financial Accountability 6.1 The Recipient must ensure that the requirements set out in this Agreement, and in any clarification or guidance issued from time to time by the Authority, are complied with. In particular the Recipient shall:

  • Health Care Accountability Ordinance If Administrative Code Chapter 12Q applies to this contract, Contractor shall comply with the requirements of Chapter 12Q. For each Covered Employee, Contractor shall provide the appropriate health benefit set forth in Section 12Q.3 of the HCAO. If Contractor chooses to offer the health plan option, such health plan shall meet the minimum standards set forth by the San Francisco Health Commission. Information about and the text of the Chapter 12Q, as well as the Health Commission’s minimum standards, is available on the web at xxxx://xxxxx.xxx/olse/hcao. Contractor is subject to the enforcement and penalty provisions in Chapter 12Q. Any Subcontract entered into by Contractor shall require any Subcontractor with 20 or more employees to comply with the requirements of the HCAO and shall contain contractual obligations substantially the same as those set forth in this Section.

  • LIABILITY AND ACCOUNTABILITY The Provider, if a non-profit entity, will provide continuous and adequate director, officer, and employee liability insurance coverage against any personal liability or accountability by reason of actions taken while acting within the scope of their authority during the existence of this Agreement and any renewal and extension thereof. Such coverage may be provided by a self-insurance program established and operating under the laws of the state of Florida.

  • Service Accountability Agreements The HSP acknowledges that if the LHIN and the HSP enter into negotiations for a subsequent service accountability agreement, subsequent funding may be interrupted if the next service accountability agreement is not executed on or before the expiration date of this Agreement.

  • A Service Accountability Agreement This Agreement is a service accountability agreement for the purposes of section 20(1) of LHSIA.

  • Federal Funding Accountability and Transparency Act of 2006 Grantee certifies that it is in compliance with the terms and requirements of 31 USC 6101.

  • Federal Funding Accountability and Transparency Act (FFATA Subrecipient shall comply with the requirements of 2 CFR part 25 Universal Identifier and System for Award Management (XXX). Subrecipient must have an active registration in XXX, xxxxx://xxx.xxx.gov/XXX/ in accordance with 2 CFR part 25, appendix A, and must have a Data Universal Numbering System (DUNS) number xxxxx://xxxxxx.xxx.xxx/webform/ Subrecipient must also comply with provisions of the Federal Funding Accountability and Transparency Act, which includes requirements on executive compensation, 2 CFR part 170 Reporting Subaward and Executive Compensation Information.

  • Federal Funding Accountability and Transparency Act Requirements A. Any recipient of funds under this agreement agrees to comply with the Federal Funding Accountability and Transparency Act (FFATA) and implementing regulations at 2 CFR Part 170, including Appendix A. This agreement is subject to the following award terms: xxxx://xxx.xxx.xxx/fdsys/pkg/FR-2010-09-14/pdf/2010-22705.pdf and xxxx://xxx.xxx.xxx/fdsys/pkg/FR-2010-09-14/pdf/2010-22706.pdf.

Time is Money Join Law Insider Premium to draft better contracts faster.